Drugs with this side effect
- 5-ASA: very rare, postmarketing
- 5-aza-2'-deoxycytidine: 37% - 90.4%
- 5-azacytidine: very common, 2.7% - 65.7%
- A77 1726: 4% - 4.47%
- Anidulafungin: 1%
- BCNU
- CAS 76095-16-4
- CAS 76420-72-9: postmarketing
- Cancidas: 1.1% - 3.2%
- Carfilzomib: 0.76% - 20.7%
- Enfuvirtide
- FAMP
- FK463: 5.36% - 76.7%
- Ge-132: postmarketing
- K779: 1% - 92%
- Kaluril
- Lisinopril: very rare, postmarketing
- MDV3100
- Meropenem anhydrous: postmarketing
- Metrodin
- NSC 352122
- PCI-32765: 23% - 57%
- Romidepsin: 3.92% - 66%
- T-A2-3
- Vancocine: postmarketing
- Zyprexa Relprevv
- abacavir
- abacavir-lamivudine: uncommon
- acetaminophen
- actinomycin D
- acyclovir
- albendazole: postmarketing
- allopurinol
- amantadine: very rare
- amiloride: postmarketing
- aminoglutethimide
- amiodarone: postmarketing
- amisulpride: postmarketing
- amoxicillin: very rare
- amprenavir
- anthracycline: 5% - 36%
- aprepitant: 2.9% - 8.9%
- aripiprazole: uncommon
- arsenic
- arsenic trioxide: common
- asenapine
- atazanavir: 9% - 12%
- atovaquone: 3% - 9%
- auranofin
- axitinib
- azithromycin: postmarketing
- aztreonam: 3.2%
- benazepril: postmarketing
- benazeprilat
- bendamustine: 21.3% - 86%
- bexarotene
- bicalutamide: 1-5%
- boceprevir: very common, 10% - 19%
- bortezomib: 0% - 24.1%
- bosentan: postmarketing
- bosutinib: 11.5%
- busulfan
- cabazitaxel: 2% - 93.5%
- cabozantinib: 2% - 35%
- candesartan: postmarketing
- candesartan cilexetil: postmarketing
- capecitabine: 1% - 87%
- captopril
- carbenicillin
- carbimazole
- carboplatin: 67%
- cefaclor: postmarketing
- cefadroxil
- cefazolin: postmarketing
- cefdinir: postmarketing
- cefditoren
- cefepime: postmarketing
- cefixime: postmarketing
- cefotaxime
- cefotetan
- cefoxitin
- cefpodoxime
- cefprozil
- ceftaroline
- ceftazidime: uncommon
- ceftizoxime
- ceftriaxone: postmarketing
- cefuroxime: postmarketing
- cefuroxime axetil
- cephalexin
- cephem: postmarketing
- chlorambucil
- chloroquine
- cidofovir: postmarketing, very common, 24.4% - 43.5%
- cilazapril: postmarketing
- cimetidine
- ciprofloxacin: rare
- cladribine: very common
- clarithromycin: postmarketing
- clindamycin
- clindamycin phosphate
- clofarabine: 63.7%
- clopidogrel: very rare, postmarketing, uncommon
- clozapine: 3%
- colchicine: postmarketing
- crizotinib: 2% - 49%
- cytarabine: 8% - 36.4%
- dabrafenib: 0% - 55%
- dalbavancin
- darunavir
- dasatinib: 20% - 80%
- deferasirox: postmarketing
- deferiprone
- delavirdine: 6.7%
- demeclocycline
- dexrazoxane
- diatrizoate
- diazepam
- dicloxacillin
- dimercaptosuccinic acid
- disopyramide
- docetaxel: very common, 1% - 95.5%
- dolutegravir
- doripenem: postmarketing, uncommon
- doxazosin
- doxorubicin: common, very common, 1.6% - 95.8%
- doxycycline: postmarketing
- doxycycline calcium
- doxycycline hyclate
- emtricitabine: postmarketing, common
- entecavir: postmarketing
- eribulin: 2% - 82%
- erlotinib
- ertapenem: 0.8% - 1.5%
- ethacrynic acid
- ethambutol
- etodolac
- etoposide: 88%
- everolimus: common, 0% - 46%
- famciclovir: 3.2%
- famotidine
- febuxostat
- fentanyl: 0% - 8.33%
- fidaxomicin: 1.03% - 2.48%
- flucloxacillin: very rare
- fluconazole: postmarketing
- fludarabine
- flurbiprofen
- fosamprenavir
- foscarnet
- fosinopril
- fosinoprilat
- fusidic acid
- ganciclovir: 11.8% - 25.7%
- gatifloxacin
- gemcitabine: very common, 0% - 89%
- haloperidol: very rare, postmarketing
- histamine
- hydralazine: uncommon
- hydroxyurea: very common
- ibuprofen: 6.67%
- idarubicin
- imatinib: postmarketing, very common, 0% - 100%
- iopamidol
- ioversol
- irbesartan: postmarketing
- irbesartan-hydrochlorothiazide
- irinotecan: 0% - 98.6%
- itraconazole: postmarketing
- ixabepilone: 2% - 36%
- lacosamide
- lamivudine: uncommon, 3% - 8%
- lamotrigine: postmarketing
- lansoprazole: postmarketing
- lapatinib: 5% - 47%
- leflunomide
- lenalidomide: postmarketing, very common, 33.4% - 79%
- lercanidipine: rare
- levetiracetam: postmarketing
- lincomycin
- linezolid
- lurasidone: rare
- lymecycline
- maraviroc
- mebendazole
- meclofenamate
- melphalan
- memantine: postmarketing
- mephenytoin
- meropenem: postmarketing
- metformin
- methotrexate
- methysergide
- metoclopramide: postmarketing
- metronidazole
- mexiletine
- mianserin
- miconazole: 0.7% - 2.1%
- milnacipran: postmarketing
- minocycline
- mirtazapine
- mitotane
- mitoxantrone
- moexiprilat
- moxifloxacin
- mycophenolate mofetil
- mycophenolic acid: postmarketing
- nafcillin
- nelarabine: 14% - 94%
- nelfinavir: postmarketing
- nevirapine: postmarketing, 8.9% - 9%
- nilotinib: very common, 11% - 42%
- norfloxacin: postmarketing
- ofatumumab: 14% - 56%
- ofloxacin
- olanzapine: postmarketing, rare, common
- olmesartan
- olsalazine
- omeprazole: postmarketing
- oxacillin
- oxaliplatin: very common, 0% - 82.2%
- oxcarbazepine: very rare
- oxytetracycline
- paclitaxel: rare, very common, 3% - 100%
- paliperidone
- pamidronate: 0% - 1%
- pazopanib: 0% - 34%
- pemetrexed: common, 0% - 58%
- penciclovir: 3.2%
- penicillin
- pentamidine
- perindopril: very rare
- perindopril erbumine: postmarketing
- perindoprilat: postmarketing
- piperacillin
- pixantrone
- pomalidomide: 2% - 52.3%
- ponatinib: 13% - 63%
- posaconazole: 3.05% - 16.3%
- pralatrexate
- prednisone
- pregabalin
- procainamide
- propranolol
- quetiapine: postmarketing
- quinidine
- rabeprazole: postmarketing
- radium: 2% - 18%
- raltegravir
- raltitrexed
- ramipril
- ranitidine
- rapamycin: postmarketing
- regorafenib: 3%
- retigabine
- retinoic acid: postmarketing
- ribavirin: very common, 1% - 40%
- rifabutin: 2% - 25%
- rifapentine
- rifaximin
- riluzole: rare
- risperidone: postmarketing
- ritonavir: 9%
- rufinamide: infrequent
- ruxolitinib: very common, 1.9% - 18.7%
- saquinavir: uncommon
- sodium cromoglycate
- sofosbuvir: very common, 0% - 17%
- sorafenib: postmarketing, common, 1% - 11%
- stavudine: very rare, postmarketing
- stiripentol
- streptozotocin
- sulfamethoxazole
- sulfasalazine
- sulindac
- sunitinib: postmarketing, 2%
- tacrolimus: postmarketing, uncommon
- tamoxifen
- telithromycin
- temozolomide: common, very common, 0% - 4%
- temsirolimus
- teniposide: 95%
- terbinafine: very rare, postmarketing
- tetracycline
- tetrahydrobiopterin
- thalidomide: postmarketing, 0.98% - 42.7%
- thymidine: 0% - 2%
- tigecycline
- tinidazole
- tipranavir: uncommon, 1%
- tofacitinib
- topiramate: very rare, postmarketing
- topotecan: very common, 1% - 97%
- trabectedin
- trametinib: 2% - 55%
- trandolapril
- trimethadione
- trimethoprim: very rare
- trimethoprim-sulfamethoxazole: very rare
- trimetrexate: 3.67% - 9.01%
- valganciclovir: 3% - 27%
- valproate
- valsartan
- vandetanib
- venlafaxine: very rare, postmarketing
- vincristine: 18.1%
- vinflunine
- vinorelbine: 5% - 90%
- vorinostat
- zafirlukast
- zalcitabine
- zanamivir
- zidovudine: common, 3%
- zidovudine/lamivudine
- zoledronic acid
- zuclopenthixol
|
Drugs with this indication
|
